Products | Nuclear Imaging | January 16, 2019

MIM SurePlan MRT

MIM SurePlan MRT

Related Content

This acquisition signifies Radformation’s commitment to driving innovation and expanding its AI-driven capabilities in cancer care.
News | Artificial Intelligence
Radformation to Accelerate AI-Based Solutions with Limbus AI Acquisition

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
Extending beyond brain tumors, empowering patients with treatment options in prostate cancer and other malignancies
News | Prostate Cancer
GT Medical Technologies, Inc and Theragenics Corporation Forge Distribution Partnership for Cesium-131

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
SunCHECK Version 5.0 addresses clinical workflow challenges with new treatment plan assessment capabilities, enhanced TPS/OIS integration, expanded QA device control, and worklist-based UI.
News | Radiation Therapy
Sun Nuclear Announces Landmark Update to Further Advance Radiation Therapy Workflows

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
The study, led by principal investigator Nitin Ohri, M.D., a professor in Radiation Oncology at the Montefiore Einstein Comprehensive Cancer Center, aims to demonstrate the feasibility of PGHD collection during proton beam radiotherapy for lung cancer
News | Proton Therapy
Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
Elekta Instrument AB recalls disposable biopsy needle kit for Leksell Stereotactic System for possibly containing microscopic stainless steel febris on the inside of the biopsy needle
News | FDA
FDA Announces Elekta Recall of Biopsy Needle Kit for Leksell Stereotactic System

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
New partnership makes outstanding radiation protection solutions available to healthcare professionals
News | Radiation Dose Management
BIOTRONIK and Texray Establish Collaboration to Distribute Texray’s Innovative Radiation Protection Products

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Radiation Therapy
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
177Lutetium-labeled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical
News | Radiopharmaceuticals and Tracers
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

April 10, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time April 10, 2024
arrow
Ga-68 has a very short half-life, which presents logistical challenges in distribution
News | Radiopharmaceuticals and Tracers
RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
During the blood pool phase, it significantly shortens the T1 and T2 relaxation times of the blood, thus achieving bright blood effects in T1-weighted imaging and dark blood effects in T2/T2*-weighted imaging. In the delay phase, by the local aggregation of ferumoxytol disrupting the uniformity of the local magnetic field, the decrease of the transverse magnetization vector Mxy is expedited, resulting in a negative contrast effect.
News | Molecular Imaging
Exploring Ferumoxytol: A Frontier in MRI Contrast Agents

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now